This study provides a comprehensive analysis of available and emerging reproductive products and technologies related to contraception and infertility treatments. The goal of this study is to provide a comprehensive range of information from detailed product analyses through industry trends, and to quantify and qualify the market for hormonal contraceptives, infertility pharmaceuticals, and for assisted reproductive technologies.
The report forecasts the following markets through 2008: The world market oral contraceptives The world market hormonal contraceptive devices The world market infertility pharmaceuticals, and The U.S. market for assisted reproductive technologies (ART).
Not included are market forecasts for infertility diagnostics or surgical procedures to treat fertility or over-the-counter contraceptives or diagnostics (such as spermicides, condoms, ovulation or pregnancy testing kits). These markets are covered in other reports such as The U.S. Market for Over-the-Counter Diagnostics and Over-the-Counter Women’s Health
World market numbers include pharmaceuticals approved by the appropriate regulatory agency in the U.S. and other countries, manufactured in the countries where the pharmaceuticals have been approved, and shipped worldwide. World market numbers in this report do not include pharmaceuticals manufactured in China or India by companies indigenous to those countries.
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information interviewed key industry officials, consultants, healthcare providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.